L. Abdel-kader

Low-level liver enzyme elevations during HAART are not associated with liver fibrosis progression among HIV/HCV-coinfected patients.

J. Macías, J. Pineda, J. Gómez-Mateos, 2006, The Journal of antimicrobial chemotherapy.

Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis.

J. Macías, J. Pineda, Á. Camacho, 2008, The Journal of antimicrobial chemotherapy.

New oral anticoagulants in nonvalvular atrial fibrillation: findings and implications of the ROCKET study.

T. Molina-López, L. Abdel-kader, M. Vega-Coca, 2013, Revista espanola de cardiologia.

Gender differences in rising trends in cutaneous malignant melanoma in Spain, 1975–98

F. Camacho, M. Conde, L. Abdel-kader, 2003, The British journal of dermatology.

Hepatic safety of tipranavir plus ritonavir (TPV/r)-based antiretroviral combinations: effect of hepatitis virus co-infection and pre-existing fibrosis.

J. Macías, J. Pineda, A. Rivero, 2008, The Journal of antimicrobial chemotherapy.

Low incidence of severe liver toxicity in patients receiving antiretroviral combinations including atazanavir.

J. Torre-Cisneros, J. Pineda, A. Rivero, 2006, The Journal of antimicrobial chemotherapy.